Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | TK2 | O00142 | 6/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TK1 | P04183 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 3/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20032236 | 1.00 | KCNN4 (0.38) | KCNN4TK2CNR2CNR1MEN1 | |
| SCHEMBL20032506 | 0.77 | CYP4A11 (0.45) | CNR2CNR1 | |
| SCHEMBL20032507 | 0.77 | CYP4A11 (0.45) | CNR2CNR1 | |
| SCHEMBL9041026 | 0.72 | KCNN4 (0.53) | KCNN4MEN1OPRM1OPRD1KMT2A | |
| SCHEMBL293540 | 0.72 | MMP8 (0.51) | KCNN4MEN1OPRM1OPRD1KMT2A | |
| SCHEMBL20032509 | 0.72 | LTB4R (0.48) | TK2TK1KIF11 | |
| SCHEMBL1881877 | 0.72 | LTB4R (0.48) | TK2TK1KIF11 | |
| SCHEMBL1887343 | 0.72 | LTB4R (0.48) | TK2TK1KIF11 | |
| SCHEMBL1885700 | 0.72 | LTB4R (0.48) | TK2TK1KIF11 | |
| SCHEMBL8354759 | 0.70 | PPARA (0.51) | CNR2CNR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519423-B1 | ENDOSOMOLYTIC AGENTS FOR GENE THERAPY | UCB Biopharma SRL (BE) | 2021-04-07 | — | — | EP | disclosed |
| US-10842884-B2 | Endosomolytic agents for gene therapy | UCB Biopharma SRL (BE) | 2020-11-24 | — | — | US | disclosed |
| US-20190298859-A1 | Endosomolytic Agents for Gene Therapy | UCB BIOPHARMA SRL (UCB BIOPHARMA SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2019-10-03 | — | — | US | disclosed |
| WO-2018060280-A1 | ENDOSOMOLYTIC AGENTS FOR GENE THERAPY | UCB BIOPHARMA SPRL (BE) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842884-B2 | Endosomolytic agents for gene therapy | YARS1, ARSA, RPS6 | KCNN4 3897/4885TK2 408/4885CNR2 1270/4885 |
| US-20190298859-A1 | Endosomolytic Agents for Gene Therapy | YARS1, ARSA, RPS6 | KCNN4 3897/4885TK2 408/4885CNR2 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.